Grail (company)

GRAIL
Company type	Public
Traded as	Nasdaq: GRAL
Industry	Biotechnology
Founded	2015
Headquarters	Menlo Park, California, United States
Products	Galleri test
Website	grail.com

Grail (styled GRAIL) is an American biotechnology company in Menlo Park, California. It was previously a subsidiary of Illumina started as a startup seeking to develop an early cancer screening test for people who do not have symptoms.^[1] Grail was spun-out from Illumina on June 24, 2024.

Their liquid biopsy (also called multi-cancer early detection test^[2]) was launched in June 2021 and is called the Galleri test. Promoted as groundbreaking, the test performed poorly in testing and Grail has subsequently faced discontent and legal action from investors claiming they have been misled about the test's potential.^[3]

^ Simon, Francoise; Glen Giovannetti (2017). "1. Digital evolution of biotechnology". Managing Biotechnology: From Science to Market in the Digital Age. John Wiley & Sons. p. 21. ISBN 978-1-119-21617-9.
^ Pyzocha, Natasha J. (October 2022). "Galleri Test for the Detection of Cancer". American Family Physician. 106 (4): 459–460. ISSN 1532-0650. PMID 36260909.
^ Cite error: The named reference hype was invoked but never defined (see the help page).

[SimonGiovannetti2017-1] Simon, Francoise; Glen Giovannetti (2017). "1. Digital evolution of biotechnology". Managing Biotechnology: From Science to Market in the Digital Age. John Wiley & Sons. p. 21. ISBN 978-1-119-21617-9.

[2] Pyzocha, Natasha J. (October 2022). "Galleri Test for the Detection of Cancer". American Family Physician. 106 (4): 459–460. ISSN 1532-0650. PMID 36260909.

[hype-3] Cite error: The named reference hype was invoked but never defined (see the help page).

[1]

[2]

[3]